Could a diabetes drug shield Kids' kidneys? new trial launches
NCT ID NCT06430684
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial aims to see if it's possible to run a study of empagliflozin, a drug already used in adults for kidney disease, in 40 children with chronic kidney disease. Participants are randomly assigned to take the drug or continue usual care for 3 months. Researchers will check if the drug is safe and if it improves blood pressure, urine markers, and heart function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin (a diabetes drug that may protect kidneys and heart)
What this could lead to
If successful, this could pave the way for larger trials testing whether empagliflozin helps slow kidney disease in children.
What could go wrong
This is a very early, small feasibility study with only 40 participants and 3 months of treatment. It is not designed to prove effectiveness, and results may not apply to all children with kidney disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••